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ABSTRACT 
Background. The value of beta-adrenergic- 
antagonist drug therapy for the prevention of initial 
episodes of gastrointestinal bleeding in patients with 
cirrhosis and esophageal varices is uncertain, both 
positive and negative study results having been re- 
ported. 
Methods. In this study, we analyzed data on indi- 
vidual patients from four randomized, controlled trials 
to assess the efficacy of this treatment. Of the 589 
patients studied, 286 received a beta-adrenergic- 
antagonist drug (propranolol in 203 and nadolol in 83) 
and 303 received placebo. 
Results. After two years, the mean ( 2 SE) percentage 
of patients who had had no upper gastrointestinal 
bleeding was 78 f 3 percent in the beta-adrenergic- 
antagonist treatment group and 65 2 3 percent in the 
control group (P = 0.002). The percentage of patients 
without fatal bleeding was 90 f 2 percent in the 
treatment group and 82 2 3 percent in the control 
group (P = 0.01). The percentage of patients surviving 
after two years was 71 2 3 percent in the treatment 
group and 68 f 3 percent in the control group 
(P  = 0.34). After age and severity of cirrhosis were 
taken into account, the survival rate was better in the 
treatment group (P= 0.09). The percentage of sur- 
viving patients who had had no bleeding after two 
years was 62 -I- 3 percent in the treatment group and 
53 -+ 3 percent in the control group (P = 0.04). Both 
propranolol and nadolol prevented a first episode of 
bleeding. Severe cirrhosis and especially the presence 
of ascites were associated with bleeding (P c 0.001) 
and death (P < 0.001) in both groups. The efficacy of 
beta-adrenergieantagonist therapy in the prevention 
of bleeding (P < 0.001) and of fatal bleeding 
(P = 0.004) and in the prevention of bleeding or 
death (P = 0.005) was the same after adjustment for 
cause and severity of cirrhosis, ascites, and size of 
varices. 
Conclusions. Propranolol and nadolol are effective 
in preventing first bleeding and reducing the mortality 
rate associated with gastrointestinal bleeding in pa- 
tients with cirrhosis, regardless of severity. 
COMMENTS 
The high mortality rate of an initial variceal bleed in 
a patient with cirrhosis and portal hypertension makes 
primary preventive treatment desirable (1). Although 
p-adrenergic antagonist drugs have been shown to 
reduce portal pressure by reducing splanchnic blood flow 
(21, the results from the published trials (3-7) and 
abstract reports (8-10) of randomized clinical trials 
using this treatment as the primary prevention against 
esophageal variceal bleeding and related death have 
been inconsistent, possibly as a result of differences in 
study populations. 
In an attempt to  resolve the inconsistency, two groups 
performed a meta-analysis of the published trials (11, 
12) and concluded that @-adrenergic blockade was 
efficacious in preventing esophageal bleeding. However, 
“classical meta-analysis” may be limited by clinical 
heterogeneity among the studies, and, more impor- 
tantly, this technique may be unable to  identify sub- 
groups in which the proposed therapy is highly effective, 
ineffective or possibly even harmful. 
Poynard and colleagues ventured a step beyond 
“classical” meta-analysis (which uses summary-level 
data) by combining the original, individual-level data 
from four (we presume the most rigorous) of the 
available studies. This innovative strategy provides an 
opportunity to adjust for clinically important differences 
among study populations using multivariate analysis 
and allows for investigation of a treatment effect in a 
greater number of subgroups than is possible with 
classical meta-analysis. For example, in contrast to  the 
previous two meta-analyses addressing these studies, 
Poynard et al.’s individual-level data demonstrated a 
trend toward improved overall survival with P-blocker 
therapy when adjusted for age and disease severity 
(p < 0.09). Furthermore, although the authors did not 
report cause-specific deaths, the data from their Table 1 
suggest that p-blockers decreased the risk of death from 
bleeding (7.3% vs. 14.2%; unadjusted relative 
risk = 0.52, 95% confidence interval = 0.32-0.85). 
Although the conclusions appear to answer the 
question of overall effectiveness of p-blockers in pre- 
venting an initial upper gastrointestinal hemorrhage, 
the specific clinical application of p-blockers in this 
setting remains ambiguous. Which clinical variables 
(either individually or in combination) predict the best 
(or no) response to @-blockers is not clear from this 
study. 
On the basis of Kaplan-Meier life table analysis for 
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patients free of bleeding, the authors concluded that 
p-blockers were effective in patients with and without 
ascites and in patients with severe and mild-to-moderate 
liver disease (i.e., virtually all patients benefited). The 
authors did state, however, that patients without ascites 
and patients with severe liver disease derived greater 
benefit from treatment. Although the Kaplan-Meier 
analysis is a very sensitive method for detecting thera- 
peutic benefit over time and under changing conditions, 
it may not have great clinical applicability for selecting 
patients who would most benefit from therapy regarding 
bleeding. Reanalysis of the data in Table 4 of the study 
using unadjusted relative risks is provided in our Table 
1. If the relative risk of bleeding is calculated over the 
2-yr study period (rather than the percentage of patients 
free of bleeding using the Kaplan-Meier method), 
treatment was more effective among patients without 
ascites and among patients with poor liver function as 
defined by a Child-Pugh score greater than or equal to 8. 
The protective efficacies (1 = relative risk) of p-blockers 
were 52% and 44% for these subgroups, respectively. No 
significant decrease in the relative risk of bleeding was 
observed with treatment in either those patients with 
good liver function (Child-Pugh score <8)  or those 
patients with ascites, although the power to detect 
clinically important risk reductions may have been 
limited. Although it may initially seem contradictory 
that p-blockers should prevent initial bleeds in patients 
with severe disease (Child-Pugh score) but not in 
patients with ascites, the five parameters used to 
calculate the Child-Pugh score do not always change in 
concert. Furthermore, p-blockers may decrease portal 
pressure to the same magnitude in patients with and 
without ascites but may not reduce the pressure gra- 
dient across the hepatic sinusoidal bed in ascitic patients 
low enough (the absolute threshold requirement is 12 
mm Hg) to prevent gastrointestinal hemorrhage caused 
by portal hypertension (13). A lack of efficacy in patients 
with ascites has been noted previously (4) and assumes 
greater importance because patients with intractable or 
tense ascites resistant to therapy were excluded from 
three of the four studies included in the Poynard et al. 
study. 
Although an appropriate "intention-to-treat" anal- 
ysis was used by the authors, this method of analysis is 
a more rigorous test for treatment effectiveness and it 
can sometimes mask or underestimate therapeutic 
efficacy. Because noncompliance was an independent 
variable associated with bleeding, it is possible that 
different results would have been obtained using an 
analysis-by-treatment-received method. 
Perhaps the most important issue concerns the 
generalizability of the results. All study patients had 
clinical and/or histological evidence of cirrhosis, esoph- 
ageal varices and no previous upper gastrointestinal 
bleeding. Exclusions, which reduced eligible participants 
by approximately 25%, included contraindications to 
P-blockers (for conditions that often coexist with cir- 




of patients Relative needed 
patients Treatment Control (95% CI) treated" 
Category of risk to be 
No ascites 16/134 36/146 0.48 (0.28-0.83)* 8 
CPS greater 261143 451139 0.56 (0.37-0.86) 7 
Ascites 331149 48/153 0.71 (0.48-1.03) - 
than or 
equal to 8 
than 8 
CPS less 22/140 37/163 0.69 (0.43-1.11) - 
~ _ _ _ _ ~ ~ ~ ~ ~ ~ ~ ~ ~  ~ 
CI = confidence interval; CPS = Child-Pugh score. 
"Calculated only if 95% CI excluded one. 
*Numbers in parentheses = range. 
both; and severe cirrhosis as defined by the Child-Pugh 
score. Finally, withdrawals caused by adverse effects of 
p-blocker therapy must be considered. In one trial (41, 
this accounted for the withdrawal of 14% of randomized 
subjects. Although p-blockers are generally considered 
to be well tolerated, relatively inexpensive and without 
major side effects, at least one preliminary report has 
found increased bleeding in propranolol-treated patients 
(9). In addition, the long-term effects of suppressing the 
elevated catecholamines present in cirrhosis are un- 
known. One possible adverse effect of such suppression 
might be an increase in the irreversible loss of nitrogen 
(14). Considering these issues, it appears premature to 
recommend either widespread endoscopic screening or 
the general use of p-blockers as prophylaxis against an 
initial episode of esophageal variceal bleeding without 
improved patient selection. Such information should 
be obtainable from the data collected by Poynard et al. 
and, it is hoped, will be forthcoming in more detailed 
reports. 
Finally, the importance of combining individual-level 
data from multiple studies needs to be emphasized. As 
outlined above, and as Poynard and colleagues have 
recognized, this approach may be the optimal method for 
effectiveness research and assessment of clinical out- 
comes (15). Perhaps it is time to consider a national 
registry for individual-level data obtained from ran- 
domized clinical trials that would preclude the necessity 
of performing meta-analyses with their potential limi- 
tations for clarifying clinical applicability. Such a reg- 
istry could be monitored through local human investi- 
gation committees; in addition, a registry would likely 
enhance the validity and precision regarding the efficacy 
of both new and old therapeutic agents. 
THOMAS F. IMPERIALE, M.D. 
ARTHUR J. MCCULLOUGH, M.D. 
Divisions of Internal Medicine 
MetroHealth Medical Center 
Case Western Reserve University 
Cleveland, Ohio 44109 
and Gastroenterology 
356 HEPATOLOGY Elsewhere HEPATOLOGY 
REFERENCES 
1. Graham DY, Lacey-Smith J. The course of patients after variceal 
hemorrhage. Gastroenterology 1981;80:800-809. 
2. Price HL, Cooperman LH, Warden JC. Control of circulation in 
man: role of p-adrenergic receptors. Circ F&s 1967;21:333. 
3. Pascal JP, Cales P, Multicenter Study Group. Propranolol in the 
prevention of first upper gastrointestinal tract hemorrhage in 
patients with cirrhosis of the liver and esophageal varices. N Engl 
J Med 1987;317:856-861. 
4. The Italian Multicenter Project for Propranolol Prevention of 
Bleeding. Propranolol prevents first gastrointestinal bleeding in 
non-ascitic cirrhotic patients. J Hepatol 1989;9:75-83. 
5. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the 
first gastrointestinal bleeding in cirrhotics: a prospective, ran- 
domized study. HEPATOLOGY 1988;8:6-9. 
6. Lebrec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, 
Chaput JC, et al. Nadolol for prophylaxis of gastrointestinal 
bleeding in patients with cirrhosis: a randomized trial. J Hepatol 
i988;7:118-125. 
7. Andreani T. Pouoon RE. Balkau BJ. Trinchet JC. Grange JD. 
I _  
Peigney N, Beaugrand M, et al. Preventive therapy of first 
gastrointestinal bleeding in patients with cirrhosis: results of a 
controlled trial comparing propranolol, endoscopic sclerotherapy 
and placebo. HEPATOLOGY 1990;12: 1413-1419. 
8. Straws E, de Sa’ MFG, Albano A, Lacet CMC, Leite MO, Maffei 
RA. A randomized controlled trial for the prevention of the first 
upper gastrointestinal bleeding due to portal hypertension in 
cirrhosis: sclerotherapy or propranolol versus control groups 
[Abstract]. MEPATOLOGY 1988;8: 1935. 
9. Colman J, P, Finch C, Dudley F. Propranolol in the 
prevention of variceal hemorrhage in alcoholic cirrhotic patients 
[Abstract]. REPATOLOGY 1990;12:851. 
10. Grace ND, Conn HO, Bosch J, Groszman FLJ, Rodes J, Wright SC, 
Matloff DS, et al. Propranolol in the prevention of first hemor- 
rhage from esophageal varices: a multi-center controlled trial. 
[Abstract]. HEPATOLOGY 1988;8: 1220. 
11. Hayes PC, Davis JM, Lewis IA, Bouchier LA. Meta-analysis of 
value of propranolol in prevention of variceal hemorrhage. Lancet 
12. Pagliano L, Burroughs AK, Sorenson TIA, Lebrec D, Morabito A, 
D’Amico G, Tine F. Therapeutic controversies and randomized 
controlled trials (RCTs): prevention of bleeding and rebleeding in 
cirrhosis. Gastroenterol Int 1989;2:71-84. 
13. Lebrec D, de Fleury P, Rueff B, Nahum H, Benhamou JP.  Portal 
hypertension, size of esophageal varices, and risk of gastrointes- 
tinal bleeding in alcoholic cirrhosis. Gastroenterology 1980;79: 
14. Lamont LS, Pate1 DG, Kalhan SC. p-Adrenergic blockade alters 
whole-body leucine metabolism in humans. J Appl Physiol 
15. Berman GD, Kottke TE, Ballard DJ. Effectiveness research and 
assessment of clinical outcome: a review of federal government 





TREATMENT OF REFRACTORY ASCITES: IS 
DIALYTIC ULTRAFILTRATION BETTER 
THAN PARACENTESIS? 
Lai KN, Li P, Law E, Swaminathan R, Nicholls MG. 
Large-volume paracentesis versus dialytic ultrafil- 
tration in the treatment of cirrhotic ascites. Q J Med 
1991;78:33-41. 
ABSTRACT 
We compared the clinical efficacy and safety of 
large-volume paracentesis and dialytic ultrafiltration 
in the treatment of refractory ascites in cirrhotic 
patients. A group of cirrhotic subjects (age 49-80 years) 
were randomly allocated to either continuous paracen- 
tesis (1-1.5 l/hour) or dialytic ultrafiltration until 
disappearance of ascites. Each patient was maintained 
on bed rest, fluid restriction (1 l/day) and a low (25 
mmol/day) sodium diet for 14 days. Five patients (three 
in the paracentesis group and two in dialytic ultrafil- 
tration group) developed massive ascites 3-5 months 
later, and received the crossover treatment. The av- 
erage volume of fluid removed was similar in the two 
groups (4.70 f 1.47 1 for dialytic ultrafiltration uersus 
4.69 * 1.84 1 for paracentesis), but the treatment 
period was significantly shorter with dialytic ultrafil- 
tration. The plasma creatinine significantly increased 
three days after paracentesis but did not increase in 
patients treated with dialytic ultrafiltration. There 
was an initial fall in mean arterial pressure during the 
first two hours of either treatment; a further fall in 
blood pressure was observed with paracentesis but not 
with dialytic ultrafiltration. Pretreatment plasma 
renin activity was elevated, but was not altered by 
either treatment. Plasma atrial natriuretic peptide 
levels were in the high-normal range before treatment. 
Paracentesis w a s  associated with a delayed fall in 
plasma atrial natriuretic peptide, while dialytic ul- 
trafiltration induced a modest but significant rise. No 
complication was experienced with dialytic ultrafil- 
tration in the two weeks following treatment, but four 
of the eight patients who underwent paracentesis had 
developed severe complications. Dialytic ultrafil- 
tration of ascitic fluid is a safe procedure in cirrhotic 
patients. Large-volume paracentesis without intra- 
venous colloid reinfusion causes complications and 
carries the potential risk of reducing the effective 
intravascular volume. 
COMmNTS 
Refractory ascites is one of the most feared complica- 
tions of advanced cirrhosis. Ascites is severe, with great 
discomfort for the patient, who almost always has 
arterial hypotension, poor kidney function and hypona- 
tremia. Diuretics are ineffective or not tolerated, and 
thus alternative treatments are required. The methods 
usually used to treat this condition are large-volume 
paracentesis and peritoneovenous shunt (l), but neither 
is completely safe nor satisfactory. In this study Lai et al. 
confirmed their previous results (2,3) on the safety and 
efficacy of dialytic ultrafiltration (DUF). 
In the 1970s a method of ascitic fluid filtration by 
Rhodiascit followed by intravenous reinfusion of the 
protein concentrate was used extensively in Europe (4). 
However, the incidence of untoward effects related to  
intravenous reinfusion, namely, disseminated intravas- 
cular coagulation, fever, sepsis and allergic reactions, 
limited clinical confidence in this technique. DUF is an 
innovation made possible by the development of hemo- 
filters that provide a sterile filtrate. The reinfusion of the 
concentrated ascites intraperitoneally instead of intra- 
venously frees the treatment from any important risk. It 
also prevents disorders related to hypovolemia, pre- 
sumably because raising the concentration of proteins of 
the peritoneal fluid leads to retrodiffusion of albumin 
into the vascular compartment (5). Therefore expansion 
